Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (15)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Droz, J. P.
Right arrow Articles by Benoit, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Droz, J. P.
Right arrow Articles by Benoit, G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1291-1298, 2003
© 2003 European Society for Medical Oncology

Original Paper

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

J. P. Droz1, X. Muracciole2, N. Mottet3, M. Ould Kaci4, J. M. Vannetzel5, N. Albin6, S. Culine7, J.-M. Rodier8, J.-L. Misset9, S. Mackenzie10,+, E. Cvitkovic10 and G. Benoit4

1 Leon Berard, Lyon; 2 Centre Hospitalier Universitaire (CHU) La Timone, Marseille; 3 CHU G. Doumergue, Nimes; 4 CHU Bicêtre, Le Kremlin Bicêtre; 5 Clinique Hartman, Neuilly; 6 Clinique Pasteur, Evreux; 7 Centre Régionale de Lutte Contre le Cancer Val d’Aurelle, Montpellier; 8 CHU Bichat, Paris; 9 CHU Paul Brousse, Villejuif; 10 Cvitkovic et Associés Consultants, Le Kremlin-Bicêtre, France

Received 20 September 2002; revised 4 April 2003; accepted 15 April 2003

Background:

A randomized, multicenter phase II study evaluating oxaliplatin alone (OXA) and oxaliplatin–5-fluorouracil combination (OXFU) in advanced hormone-refractory prostate cancer (HRPC) patients.

Patients and methods:

Metastatic, pathologically proven prostate carcinoma patients, progressing despite anti-androgen therapy, received intravenous OXA (130 mg/m2 over 2 h), alone or with 5-FU (1000 mg/m2/day, continuous intravenous infusion, days 1–4), every 3 weeks. OXA patients could receive OXFU after treatment failure.

Results:

Fifty-four patients (26 OXA, 28 OXFU) from nine centers received 269 treatment cycles (106 OXA, 163 OXFU; median 3.5 OXA or 5 OXFU cycles per patient; range 1–10 or 1–14, respectively). Patient characteristics were similar in both arms. Three partial responses (PR) occurred in 21 evaluable OXA patients [14%; 95% confidence interval (CI) 1% to 30%], and in five of 26 evaluable OXFU patients (19%; 95% CI 7% to 39%). Clinical benefit response (pain, performance status and weight changes) was assessed in 20 OXA and 22 OXFU symptomatic patients, with more responders in the OXFU arm (39% compared with 12%). Median time to progression in the OXA and OXFU arms was 2.6 and 3.4 months, and median overall survival was 9.4 and 11.4 months, respectively. Hematotoxicity was common, but mostly mild to moderate. Neutropenia was more common in OXFU than OXA patients. After oxaliplatin failure, 12 patients received 46 cycles of OXFU and one of 11 evaluable patients had a PR.

Conclusion:

The objective response rate, palliation benefit, survival and manageable toxicity obtained in this heavily pretreated HRPC population with OXFU merit further study.

Key words: DACH-platinum, 5-fluorouracil, HRPC, oxaliplatin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.